Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intravenous InfusionsXGHA:IIL +6.98%3 Earnings per Share (Diluted) is GHS as of . 20. GuruFocus rates XGHA:IIL with a GF Score™ of 3/100. Among 787 Drug Manufacturers companies, Intravenous Infusions ranks worse than 127064.68% on this metric.
Intravenous Infusions (XGHA:IIL) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Intravenous Infusions Earnings per Share (Diluted) Related Terms
Intravenous Infusions Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Intravenous Infusions's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions Earnings per Share (Diluted) Chart
Intravenous Infusions Annual Data
Trend
Earnings per Share (Diluted)
Intravenous Infusions Semi-Annual Data
Earnings per Share (Diluted)
XGHA:IIL vs PTLF, PCYN, YBAO: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intravenous Infusions PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's PE Ratio distribution charts can be found below:
* The bar in red indicates where Intravenous Infusions's PE Ratio falls into.
Intravenous Infusions Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Intravenous Infusions's Earnings Per Share (Diluted) for the fiscal year that ended in . 20 is calculated as
What does a Earnings per Share (Diluted) of GHS mean?
Intravenous Infusions (XGHA:IIL) has a Earnings per Share (Diluted) of GHS as of . 20. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Intravenous Infusions and its competitors. According to the industry distribution chart, Intravenous Infusions ranks #999999 out of 787 companies in the Drug Manufacturers industry.
Is Intravenous Infusions' Earnings per Share (Diluted) too high?
Intravenous Infusions' current Earnings per Share (Diluted) is GHS. Based on the distribution chart, Intravenous Infusions ranks #999999 out of 787 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Intravenous Infusions has a GF Score™ of 3/100, reflecting its overall financial health beyond just this single metric.
How does Intravenous Infusions' Earnings per Share (Diluted) compare to PTLF and PCYN?
According to the Drug Manufacturers industry distribution chart, Intravenous Infusions ranks #999999 out of 787 companies for Earnings per Share (Diluted). This places Intravenous Infusions in the lower half of its industry. The industry median Earnings per Share (Diluted) is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Intravenous Infusions and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intravenous Infusions's current Earnings per Share (Diluted) is GHS. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Earnings per Share (Diluted) of GHS. The current Earnings per Share (Diluted) is GHS. Intravenous Infusions' overall GF Score™ is 3/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Earnings per Share (Diluted) is GHS as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.
3GF Score
Get the complete analysis for XGHA:IIL
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:IIL has been successfully added to your 
